SCHEMBL2566490

SCHEMBL2566490

CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(C)NC(=O)N1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 19/20 0.70
GRK2 P25098 9/20 0.70
GRK5 P34947 7/20 0.70
RPS6KA1 Q15418 6/20 0.70
RPS6KB1 P23443 6/20 0.70
GRK1 Q15835 1/20 0.56
ROCK2 O75116 3/20 0.55
PRKD3 O94806 1/20 0.55
MAP4K4 O95819 1/20 0.55
CLK2 P49760 1/20 0.55
DYRK1A Q13627 1/20 0.55
PRKG1 Q13976 1/20 0.55
PRKD2 Q9BZL6 1/20 0.55
CLK4 Q9HAZ1 1/20 0.55
SGK2 Q9HBY8 1/20 0.55
STK17A Q9UEE5 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2565505 0.84 GRK2 (0.82) ROCK1GRK2GRK5RPS6KA1RPS6KB1
SCHEMBL2562798 0.84 GRK2 (0.69) ROCK1GRK2GRK5RPS6KA1RPS6KB1
SCHEMBL2568887 0.83 GRK2 (0.64) ROCK1GRK2GRK5RPS6KA1RPS6KB1
SCHEMBL2563079 0.83 GRK2 (0.84) ROCK1GRK2GRK5RPS6KA1RPS6KB1
SCHEMBL2570395 0.83 GRK2 (0.84) ROCK1GRK2GRK5RPS6KA1RPS6KB1
SCHEMBL2569243 0.83 GRK2 (0.81) ROCK1GRK2GRK5RPS6KA1RPS6KB1
SCHEMBL2566546 0.83 GRK2 (0.82) ROCK1GRK2GRK5RPS6KA1RPS6KB1
Gsk-180736A SCHEMBL2569804 0.83 GRK2 (1.00) ROCK1GRK2GRK5RPS6KA1RPS6KB1
SCHEMBL2569353 0.83 GRK2 (0.82) ROCK1GRK2GRK5RPS6KA1RPS6KB1
SCHEMBL2567814 0.83 GRK2 (0.76) ROCK1GRK2GRK5RPS6KA1RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633740-B1 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-11-09 EP claimed
US-7560467-B2 Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-14 US claimed
US-20070099944-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-05-03 US claimed
EP-1633740-B1 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-11-09 EP disclosed
EP-1633740-B1 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-11-09 EP disclosed
US-7560467-B2 Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-14 US disclosed
US-7560467-B2 Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-14 US disclosed
US-7560467-B2 Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-14 US disclosed
EP-1633740-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-11-19 EP disclosed
US-20070099944-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-05-03 US disclosed
US-20070099944-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-05-03 US disclosed
US-20070099944-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-05-03 US disclosed
EP-1633740-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2006-03-15 EP disclosed
WO-2004112719-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099944-A1 Chemical compounds ROCK1, ROCK2, CIT ROCK1 1/4885GRK2 165/4885GRK5 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.